drugset / Trial / NCT05493631
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of subcutaneous MG1113 in the multiple ascending dose study in patients with severe hemophilia.
Timeline
- Start
- 2022-08-24
- Primary completion
- 2024-12-11
- Completion
- 2024-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MG1113 | Protein / enzyme biologic | 2 mg/kg | Subcutaneous |